GlassScriptPhysician profile
Emmanuel O Odi
NPI 1215976451
$7,727.80
in general payments reported to CMS, 2019-2025
38 companies · $30.44 in 2025
The $30.44 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,768 · 2020: $1,959 · 2021: $2,349 · 2022: $1,621 · 2025: $30.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $30.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $30.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,249.08 | 2019-2022 | |
| Lilly USA, LLC | $791.72 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $704.61 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $529.04 | 2019-2022 | |
| Abbvie INC. | $521.89 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $398.12 | 2019-2022 | |
| Amgen INC. | $351.66 | 2019-2025 | Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $326.05 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $319.84 | 2019-2021 | |
| Glaxosmithkline, LLC. | $282.54 | 2019-2022 | |
| Pfizer INC. | $259.11 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $226.57 | 2020-2021 | |
| Vivus LLC | $200.90 | 2019-2021 | |
| Assertio Therapeutics, INC. | $195.19 | 2019-2020 | |
| Allergan, INC. | $178.95 | 2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Odi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.